Aurobindo Pharma Limited — Q4 FY25
Aurobindo Pharma delivered a strong Q4 FY25 with revenue of INR 8,382 crore (+11% YoY) and EBITDA of INR 1,792 crore (21.4% margin), driven by volume growth in US and Europe, st...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
FY25 EBITDA margin guidance of 21%-22%
Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1